Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/12/2019 10:30 PDT] Fennec Pharmaceuticals Inc. (NASDAQ:FENC), Down By 100.00% ($3.95) From $3.950 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/29/2019 07:32 PDT] FENC Expected to Trade Down After Bearish Patterns Develop
• [05/01/2019 08:17 PDT] FENC Expected to Trade Down After Bearish Patterns Develop